Genopep 1

Drug Profile

Genopep 1

Alternative Names: GNP 1; ISSAR 1

Latest Information Update: 16 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Issar Pharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Aug 2016 Issar Pharmaceuticals has patents pending for genopep 1 (Issar Pharmaceuticals pipeline, August 2016)
  • 11 Aug 2016 Issar Pharmaceuticals files a phase II clinical trial dossier in India for Solid tumours (Issar Pharmaceuticals pipeline, August 2016)
  • 28 Apr 2016 Genopep 1 is available for licensing as of 28 Apr 2016. http://issar.co.in/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top